Prescription Drug Promotion from 2001-2014: Data from the US Food and Drug Administration

被引:11
|
作者
Sullivan, Helen W. [1 ]
Aikin, Kathryn J. [1 ]
Chung-Davies, Eunice [1 ]
Wade, Michael [1 ]
机构
[1] US FDA, Silver Spring, MD USA
来源
PLOS ONE | 2016年 / 11卷 / 05期
关键词
CONSUMER; TELEVISION; EXPOSURE;
D O I
10.1371/journal.pone.0155035
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The volume of prescription drug promotion over time is often measured by assessing changes in ad spending. However, this method obscures the fact that some types of advertising are more expensive than others. Another way to measure the changes in prescription drug promotion over time is to assess the number of promotional pieces submitted to the U.S. Food and Drug Administration (FDA). Form FDA 2253 collects information such as the date submitted and the type of material submitted. We analyzed data from Forms FDA 2253 received from 2001-2014. We examined the frequency of submissions by audience (consumer and healthcare professional) and type of promotional material. There was a noted increase in prescription drug promotion submissions across all media in the early 2000s. Although non-Internet promotion submissions have since plateaued, Internet promotion continued to increase. These results can help public health advocates and regulators focus attention and resources.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Welcome (?) guidance from the Food and Drug Administration
    Lindblad, WJ
    WOUND REPAIR AND REGENERATION, 2001, 9 (04) : 257 - 257
  • [42] An update from the US Food and Drug Administration on real-world data and real-world evidence
    Dal Pan, Gerald J.
    ANNALS OF ONCOLOGY, 2022, 33 : S407 - S407
  • [43] NOVEL DRUG APPROVALS BY THE US FOOD AND DRUG ADMINISTRATION IN RARE DISEASES: FINDINGS FROM 2020-2023
    Dubey, A.
    Gupta, P.
    Ranjan, N.
    Ray, P.
    Kumar, J.
    Shaikh, J.
    VALUE IN HEALTH, 2024, 27 (06) : S216 - S216
  • [44] Assessing Adverse Drug Reactions from Psychotropic Medications Reported to the US Food and Drug Administration in Older Adults
    Gray, Matthew P.
    Dziuba, Gabrielle
    Quach, Karen
    Wong, Adrian
    Smithburger, Pamela L.
    Seybert, Amy L.
    Kane-Gill, Sandra L.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2019, 27 (02): : 181 - 185
  • [45] Drug Induced Anaphylaxis in Korean: Data from the Adverse Drug Reaction Reporting System to the Korea Food and Drug Administration
    Jung, J. W.
    Kang, H. R.
    Lee, Y. R.
    DRUG SAFETY, 2013, 36 (09) : 850 - 850
  • [46] Direct Oral Anticoagulants and Menorrhagia in Premenopausal Women: Data from the Food and Drug Administration Adverse Event Reporting System and US Drug Utilization
    Tobenkin, A.
    Mohamoud, M.
    Munoz, M.
    Waldron, P.
    HAEMOPHILIA, 2017, 23 : 43 - 43
  • [47] Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications
    Khin, Ni A.
    Chen, Yeh-Fong
    Yang, Yang
    Yang, Peiling
    Laughren, Thomas P.
    JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (04) : 464 - 472
  • [48] Surgical Innovation and the US Food and Drug Administration
    Cundiff, Geoffrey W.
    FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY, 2019, 25 (04): : 263 - 264
  • [49] US Food and Drug Administration pushed to change
    McCarthy, M
    LANCET, 2006, 367 (9523): : 1643 - 1644
  • [50] Increasing Transparency at the US Food and Drug Administration
    Steinbrook, Robert
    JAMA INTERNAL MEDICINE, 2019, 179 (08) : 1146 - 1147